Literature DB >> 28122802

Hereditary leiomyomatosis and renal cell cancer syndrome: a family affair.

Jiasian Teh1, Ned Kinnear1, Hannah Douglass-Molloy2, Derek Barrry Hennessey1.   

Abstract

A 49-year-old woman with cutaneous and uterine leiomyomas, flank pain and a family history of hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome sought genetic testing. She was found to harbour a fumarate hydratase (FH) genetic mutation and a previously undetected renal tumour. The patient underwent radical nephrectomy, and remains well at follow-up. HLRCC syndrome is a rare autosomal dominant disease, with patients at increased risk for cutaneous leiomyomas, early-onset uterine leiomyomas and aggressive renal carcinoma. Although the syndrome may manifest life-threatening complications, outcomes may be improved by preventative family screening and surveillance, compelling early diagnosis. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28122802      PMCID: PMC5278315          DOI: 10.1136/bcr-2016-218270

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.

Authors:  D L Smit; A R Mensenkamp; S Badeloe; M H Breuning; M E H Simon; K Y van Spaendonck; C M Aalfs; J G Post; S Shanley; I P C Krapels; L H Hoefsloot; R J A van Moorselaar; T M Starink; J-P Bayley; J Frank; M A M van Steensel; F H Menko
Journal:  Clin Genet       Date:  2011-01       Impact factor: 4.438

2.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.

Authors:  Steven C Smith; Kiril Trpkov; Ying-Bei Chen; Rohit Mehra; Deepika Sirohi; Chisato Ohe; Andi K Cani; Daniel H Hovelson; Kei Omata; Jonathan B McHugh; Wolfram Jochum; Maurizio Colecchia; Mitual Amin; Mukul K Divatia; Ondřej Hes; Santosh Menon; Isabela Werneck da Cunha; Sergio Tripodi; Fadi Brimo; Anthony J Gill; Adeboye O Osunkoya; Cristina Magi-Galluzzi; Mathilde Sibony; Sean R Williamson; Gabriella Nesi; Maria M Picken; Fiona Maclean; Abbas Agaimy; Liang Cheng; Jonathan I Epstein; Victor E Reuter; Satish K Tickoo; Scott A Tomlins; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

Review 4.  Integration of surgery and systemic therapy for renal cell carcinoma.

Authors:  Patrick A Kenney; Christopher G Wood
Journal:  Urol Clin North Am       Date:  2012-05       Impact factor: 2.241

Review 5.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.

Authors:  Fred H Menko; Eamonn R Maher; Laura S Schmidt; Lindsay A Middelton; Kristiina Aittomäki; Ian Tomlinson; Stéphane Richard; W Marston Linehan
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

6.  Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics.

Authors:  Heli J Lehtonen
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.